Utility Valuations for Outcome States of Colorectal Cancer

Ness, Reid M.; Holmes, Ann M.; Klein, Robert J.; Dittus, Robert S.

doi:10.1111/j.1572-0241.1999.01157.x

Cited by 166 publications

(128 citation statements)

References 35 publications

Supporting

Mentioning

127

Contrasting

Order By: Relevance

“…Warren et al 64 Gatto et al 13 Levin et al 66 Ness et al 66 Other diseases We used utility scores published by Sullivan and Ghushchyan. 67,68 Sullivan et al 67,68 population of 100,000 individuals aged 50 years old, representative of the U.S. population.…”

mentioning

confidence: 99%

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Dinh¹,

Alperin²,

Walter

et al. 2012

J GEN INTERN MED

View full text Add to dashboard Cite

mentioning

confidence: 99%

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Dinh¹,

Alperin²,

Walter

et al. 2012

J GEN INTERN MED

View full text Add to dashboard Cite

“…The valuations they provided were of similar magnitude as utilities found in earlier research on cancer patients. Ness et al (1999) measured standard gamble scores for outcome states of colorectal cancer in a sample of 81 patients who had previously undergone resection of colorectal carcinoma. They found standard gamble scores of 0.84 for 'own health', 0.74 for the health state 'disease free after resection' and 0.25 for 'metastatic/irresectable'.…”

Section: Discussionmentioning

confidence: 99%

Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences

et al. 2002

View full text Add to dashboard Cite

To assess patients' utilities for health state outcomes after transhiatal or transthoracic oesophagectomy for oesophageal cancer and to investigate the patients' treatment preferences for either procedure. The study group consisted of 48 patients who had undergone either transhiatal or transthoracic oesophagectomy. In an interview they were presented with eight possible health states following oesophagectomy. Visual Analogue Scale and standard gamble techniques were used to measure utilities. Treatment preference for either transhiatal or transthoracic oesophagectomy was assessed. Highest scores were found for the patients' own current health state (Visual Analogue Scale: 0.77; standard gamble: 0.97). Lowest scores were elicited for the health state ‘irresectable tumour’ (Visual Analogue Scale: 0.13; standard gamble: 0.34). The Visual Analogue Scale method produced lower estimates ( P <0.001) than the standard gamble method for all health states. Most patient characteristics and clinical factors did not correlate with the utilities. Ninety-five per cent of patients who underwent a transthoracic procedure and 52% of patients who underwent a transhiatal resection would prefer the transthoracic treatment. No significant associations between any patient characteristics or clinical characteristics and treatment preference were found. Utilities after transhiatal or transthoracic oesophagectomy were robust because they generally did not vary by patient or clinical characteristics. Overall, most patients preferred the transthoracic procedure. British Journal of Cancer (2002) 86 , 851–857. DOI: 10.1038/sj/bjc/6600203 www.bjcancer.com © 2002 Cancer Research UK

show abstract

“…Cancer: Based again on the studies of van den Brink et al 12 and Ness et al 13 , utility values for relapse were reported to be in the range 0.24-0.67. We therefore assumed a midpoint value of 0.45 in the base-case analysis for patients with relapsed colon cancer.…”

Section: Utility Associated With Relapsed Stage III Colonmentioning

confidence: 99%

“…Utility Associated with "Disease-free" Stage III Colon Cancer: Based on the studies of van den Brink et al 12 and Ness et al 13 , the utility values for stage iii colon cancer patients diagnosed with the disease or surviving disease-free were in the range 0.63-0.89. A midpoint value of 0.76 was chosen, meaning that each patient entered the model with a utility of 0.76.…”

Section: Quality Of Life and Health Utilitymentioning

confidence: 99%

Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada

Attard¹,

Maroun

Alloul

et al. 2010

Current Oncology

View full text Add to dashboard Cite

ObjectiveThe cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5fu/lv)-the folfox regimen-was compared with that of 5fu/lv alone as adjuvant therapy for patients with stage iii colon cancer, from the perspective of the Cancer Care Ontario New Drug Funding Program. In the mosaic (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) trial, the folfox regimen significantly improved disease-free survival. The mosaic trial formed the basis of the present analysis. MethodologyExtrapolated patient-level data from the mosaic trial were used to model patient outcomes from treatment until death. Utilities were obtained from the literature. Resource utilization data were derived from the mosaic trial and supplemented with data from the literature. Unit costs were obtained from the Ontario Ministry of Health and Long-Term Care, the London Health Sciences Centre, and the literature. ResultsLifetime incremental cost-effectiveness ratios for folfox compared with 5fu/lv were CA$14,266 per disease-free year, CA$23,598 per life-year saved, and CA$24,104 per quality adjusted life-year (qaly) gained, discounting costs and outcomes at 5% per annum. These results were stable for a wide range of inputs; only utility values associated with relapse seemed to influence the cost-effectiveness ratios observed. ConclusionsWith an incremental cost of CA$24,104 per qaly gained, folfox is a cost-effective adjuvant treatment for stage iii colon cancer. Compared with 5fu/lv alone, this regimen offers better clinical outcomes and provides good value for money.

show abstract

Utility Valuations for Outcome States of Colorectal Cancer

Cited by 166 publications

References 35 publications

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness Study in Diabetic Populations

Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences

Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada

Contact Info

Product

Resources

About